Therapeutic Alliances for Optimizing the Management of Patients with Prostate Cancer: SOGUG Multidisciplinary Expert Panel Recommendations

Autores de I3PT

• 

  Enrique Gallardo Diaz

  Autor

• Jesús Muñoz Rodríguez

  Autor

Participantes ajenos a I3PT

• González-del-Alba, A
• Ballesteros, CM
• Arranz, JA
• Sarrió, RG
• Campos, FL
• Méndez-Vidal, MJ
• de Iturriaga, AG

Grupos de Investigación

• Investigació Biomèdica en càncer

  

  Investigador

  Enrique Gallardo Diaz

Abstract

A group of Spanish experts of different specialties participated in the ENFOCA2 project, promoted by the Spanish Oncology Genitourinary Group (SOGUG), which was designed to provide updated information on current and novel aspects contributing to the optimal care of prostate cancer (PCa) patients. In localized disease, it is important to implement strategic alliances with other institutions for improving adherence to active surveillance in low-risk groups and to explore genetic testing for a better indication of focal therapy. Local control of the disease should be maximized to prevent local failure and biochemical recurrence. In patients with locally advanced disease, with PSMA PET/CT-positive lesions in M0 staging on conventional imaging techniques, therapeutic decisions should be carefully evaluated due to insufficient evidence regarding the gold standard in this setting. In patients with metastatic castration-resistant PCa (mCRPC), assessment of BRCA somatic and germline mutations provides prognostic information and familial cancer risk and informs treatment decisions. Combinations of androgen receptor signaling inhibitor (ARSi) agents and poly-ADP ribose polymerase inhibitors (PARPi) are emerging alternatives for advanced PCa. The oldest segment of PCa patients (>70 years of age) may require geriatric assessment to evaluate physical and functional reserves, tailoring treatment to their individual characteristics and circumstances. The concept of a comprehensive multidisciplinary approach together with inter-center and/or inter-specialty therapeutic alliances should be implemented in the routine care of patients with PCa.

Keywords

• prostate cancer; multidisciplinary team; therapeutic alliances; localized disease; locally advanced disease; biochemical recurrence; metastatic disease; geriatric assessment